Juan A. Paez

Madrid, MD 28006, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

A Multimodal Sequence-to-Sequence Model for Automatic Assignment of ATC Codes in Drug Discovery and Repurposing.

A Multimodal Sequence-to-Sequence Model for Automatic Assignment of ATC Codes in Drug Discovery and Repurposing.

Journal: Journal of chemical information and modeling

Published: April 14, 2026

Correction to "AI-Driven De Novo Design and Development of Nontoxic DYRK1A Inhibitors".

Correction to "AI-Driven De Novo Design and Development of Nontoxic DYRK1A Inhibitors".

Journal: Journal of medicinal chemistry

Published: December 08, 2025

AI-Driven De Novo Design and Development of Nontoxic DYRK1A Inhibitors.

AI-Driven De Novo Design and Development of Nontoxic DYRK1A Inhibitors.

Journal: Journal of medicinal chemistry

Published: May 03, 2025

Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model.

Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model.

Journal: Brain, behavior, and immunity

Published: September 23, 2024

Multitask Deep Neural Networks for Ames Mutagenicity Prediction.

Multitask Deep Neural Networks for Ames Mutagenicity Prediction.

Journal: Journal of chemical information and modeling

Published: September 06, 2022

Multitarget drugs as potential therapeutic agents for alzheimer's disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors.

Multitarget drugs as potential therapeutic agents for alzheimer's disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors.

Journal: Journal of enzyme inhibition and medicinal chemistry

Published: September 02, 2022

New cannabinoid receptor antagonists as pharmacological tool.

New cannabinoid receptor antagonists as pharmacological tool.

Journal: Bioorganic & medicinal chemistry

Published: April 18, 2020

Targeting Cannabinoid Receptor Activation and BACE-1 Activity Counteracts TgAPP Mice Memory Impairment and Alzheimer's Disease Lymphoblast Alterations.

Targeting Cannabinoid Receptor Activation and BACE-1 Activity Counteracts TgAPP Mice Memory Impairment and Alzheimer's Disease Lymphoblast Alterations.

Journal: Molecular neurobiology

Published: May 31, 2019

QSAR Classification Models for Predicting the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer's Disease.

QSAR Classification Models for Predicting the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer's Disease.

Journal: Scientific reports

Published: January 31, 2019

Indazolylketones as new multitarget cannabinoid drugs.

Indazolylketones as new multitarget cannabinoid drugs.

Journal: European journal of medicinal chemistry

Published: October 24, 2018

Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease.

Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease.

Journal: CNS drugs

Published: May 08, 2018

Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's Disease and Less Well-Known Diseases.

Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's Disease and Less Well-Known Diseases.

Journal: Current medicinal chemistry

Published: December 21, 2017

Showing 1-12 of 18

Last Updated: 09/26/2026